Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma (MEITL)
An aggressive, rare T-cell lymphoma arising in the small intestine that requires prompt diagnosis and specialist-led treatment planning.
- CD8+ Intestinal T-Cell Origin
- Often Diagnosed at Surgery
- Requires Multidisciplinary Care
- Most Common In
- Adults, Asian populations
- Primary Site
- Small Intestine
- Disease Behavior
- Aggressive
- Advanced Therapies
- Clinical Trials, Novel Agents
Condition Overview
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma (MEITL) is a rare and aggressive form of primary intestinal T-cell lymphoma. It arises from CD8-positive cytotoxic T cells that infiltrate the lining of the small intestine, and it often presents with abdominal pain, bowel obstruction, or perforation that brings patients to surgery before a diagnosis is made.
Types and Subtypes
MEITL is generally described as a single, monomorphic disease entity rather than a group of distinct subtypes, though presentations can vary by extent of bowel involvement.
Symptoms and Signs
Symptoms of MEITL are often nonspecific and gastrointestinal in nature, which can delay diagnosis until the disease has progressed or caused an acute complication.
Causes and Risk Factors
The exact cause of MEITL is not fully understood, but certain associations have been identified that may increase risk.
Diagnosis and Investigations
Diagnosis of MEITL typically requires tissue confirmation, often obtained during surgery performed for an acute abdominal complication, supported by imaging and laboratory workup.
Staging and Risk Groups
MEITL is staged using lymphoma staging systems adapted for gastrointestinal lymphomas, factoring in the extent of bowel and extra-intestinal involvement.
Standard Treatment
Treatment for MEITL typically combines surgery (often performed emergently) with systemic chemotherapy, given the aggressive nature of the disease.
Advanced & Emerging Therapies
Because MEITL is rare and often resistant to standard chemotherapy, patients may benefit from exploring clinical trials and newer targeted approaches.
Cellular Therapy
Allogeneic Stem Cell Transplant
Offers a potentially durable option for eligible patients with responsive or relapsed disease.
Targeted Therapy
Novel T-Cell Lymphoma Agents
Newer agents being studied for peripheral and intestinal T-cell lymphomas may offer additional options for relapsed or refractory disease.
International Access
China-Based Specialist Centers
Patients may explore access to specialist hematology-oncology centers with experience managing rare intestinal lymphomas.
Biomarkers & Precision Medicine
Molecular profiling is increasingly used to better characterize MEITL and identify potential targets for emerging therapies.
When to Seek 2nd Opinion
Given how rare MEITL is, a second opinion from a center experienced in intestinal T-cell lymphomas can be valuable at several points in care.
Clinical Trials & Research
Prognosis & Outcomes
MEITL is generally considered an aggressive lymphoma, and outcomes depend heavily on disease extent at diagnosis, response to initial therapy, and the ability to proceed to consolidation strategies such as transplant.
Supportive Care
Supportive care plays an important role in managing the gastrointestinal and nutritional effects of MEITL and its treatment.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with MEITL access specialist review of pathology and imaging, connect with experienced lymphoma centers, and explore clinical trial and transplant options.
Get a free case reviewFrequently Asked Questions
MEITL is a rare, aggressive lymphoma that develops from T cells in the lining of the small intestine, often presenting with abdominal symptoms or an acute surgical emergency.
MEITL was previously classified as Type II Enteropathy-Associated T-Cell Lymphoma (EATL) but is now recognized as a distinct disease entity with its own molecular profile.
Unlike Type I EATL, MEITL is generally not strongly associated with celiac disease.
Diagnosis usually requires a tissue biopsy, often obtained during surgery for bowel obstruction or perforation, along with immunohistochemistry and molecular studies.
Treatment typically involves surgical resection followed by combination chemotherapy, with consideration of stem cell transplantation for eligible patients.
Outcomes vary by disease extent and treatment response; some patients achieve durable remission, particularly with localized disease and good treatment response. A specialist can provide individualized guidance.
Because MEITL is rare, trial availability varies; patients are encouraged to discuss eligibility for peripheral T-cell lymphoma trials with a specialist center.
Specialist hematology-oncology centers with lymphoma expertise, including international centers, can offer experience managing this rare disease.
Yes. CancerFax can help review medical reports, coordinate second opinions with lymphoma specialists, and explore advanced therapy and clinical trial access, including international coordination.
Have a MEITL Diagnosis or Pathology Report?
Send your medical reports to CancerFax for review and explore second opinion and advanced therapy options.